Cell Therapy Companies Make Strong Progress from October 2012 to March 2013 Amid Mixed Stock Market Sentiment
Chris Mason(Oak Ridge National Laboratory), Brock Reeve(Harvard Stem Cell Institute), J. Mason(Kingston University), Emily J Culme-Seymour(GlaxoSmithKline (United Kingdom)), Gregory A. Bonfiglio
Cited by 19
Related Papers
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
BTRFS
|ACM Transactions on Storage|2013|381
Lancet Commission: Stem cells and regenerative medicine
|The Lancet|2017|276
Cell Therapy Industry: Billion Dollar Global Business with Unlimited Potential
|Regenerative Medicine|2011|144
Peak Serum: Implications of Serum Supply for Cell Therapy Manufacturing
|Regenerative Medicine|2011|144